About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials | 8,034 Studies Recruiting

Clinical TrialsLung Cancer

Lung Cancer Clinical Trials

Browse 8,034 clinical trials for lung cancer. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 2361-2380 of 8,034 trials

CompletedAVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung CancerThis open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small…NCT00961415·Béziers and 90 others

Related Searches

nsclctrials sclctrials lung carcinomatrials

Data from ClinicalTrials.govTerms

CompletedRadiotherapy for NSCLC to a Individualized MLDOur group has shown in a modeling study that increasing the radiation dose to pre-specified normal tissue dose constrains could lead to increased TCP with the same NTCP.NCT00573040·Maastricht, Limburg

RecruitingOvercoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCThis Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with…NCT07158489·Baden and 6 others

RecruitingStudy of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung CancerAll subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 10 years post last vaccine for those patients who…NCT01720836·Pittsburgh, Pennsylvania

CompletedA Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least…NCT01124864·Los Angeles, California and 21 others

CompletedA Study of Intravenous XMT-1001 in Patients With Advanced Solid TumorsThis amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and…NCT00455052·Scottsdale, Arizona and 11 others

CompletedFeasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung CancerThis study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B)…NCT00269152·Bordeaux and 17 others

UnknownA Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLCThis is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients…NCT04982549·Zhengzhou, Henan and 1 other

RecruitingAK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung CancerAK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile…NCT05377658·Zhengzhou, Henan

CompletedEvaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLCThe aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is…NCT00463515·Antwerp, Antwerp and 2 others

CompletedRecombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerThis phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and…NCT01727076·Palo Alto, California and 4 others

TerminatedA Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus ErlotinibThe primary objective of this study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in…NCT01377376·Osaka

CompletedSafety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered TumorsThis study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET)…NCT03780517·Philadelphia, Pennsylvania and 20 others

CompletedA Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M MutationsThis trial is divided into Part A and Part B. The primary objective of Part A is to establish the Maximal Tolerated Dose of intermittent high dose afatinib.NCT01647711·Aurora, Colorado and 1 other

Active not recruitingRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsThe purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination…NCT07468071·Sint-Niklaas, Oost Vlaanderen and 20 others

RecruitingBostonGene and Exigent Genomic INsight StudyThe BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients.NCT06272864·Rogers, Arkansas and 6 others

CompletedErlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLCErlotinib is a drug which targets non small cell lung cancer with a genetic change (mutation) in the epidermal growth factor receptor (EGFR).NCT00997334·Boston, Massachusetts and 1 other

Active not recruitingNivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerThis phase I/II trial studies the side effects and best dose of nivolumab when giving together with stereotactic radiosurgery or whole brain radiotherapy with or without…NCT02696993·Houston, Texas

CompletedCombination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsThe third generation epidermal growth factor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M…NCT04184921·Chongqing, Chongqing Municipality

TerminatedA Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced MalignanciesA Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select…NCT05861947·Visakhapatnam, Andhra Pradesh and 5 others

PreviousPage 119 of 402Next